LongRiver Investments Wins Nine Accolades Across Five Prestigious Lists, with Three Portfolio Companies Recognized as 'Top Innovators in Pharmaceutical R&D'

Rona Therapeutics

Rona Therapeutics, a leader in innovative RNA therapies, leverages its self-developed nucleic acid chemistry and delivery platform to focus on the treatment of cardiometabolic diseases, obesity, and neurological disorders. The company is committed to developing differentiated and innovative best-in-class and first-in-class siRNA drugs to address treatment challenges in cardiovascular diseases, obesity, and metabolic dysfunction-associated steatohepatitis (MASH).

In March 2025, Rona Therapeutics completed a $25 million Pre-B round of financing, further advancing the global clinical pipeline layout and innovative drug development.

Hanchen XingTai

Focusing on the fields of oncology and autoimmune diseases, Rona Therapeutics primarily develops innovative drugs with novel peptide-based molecular entities. The company has built a diversified and sustainable innovative technology platform, establishing a distinctive pipeline for solid tumors, autoimmune diseases, allergies, and inflammation.

Ocugen

Focusing on the field of innovative macromolecular ophthalmic drugs, the progress of the core project OCUL101 has been particularly remarkable. This FIC (First-in-Class) ophthalmic bispecific antibody drug, independently developed by Ocumension Therapeutics, received FDA IND approval in November 2024 and obtained the NMPA CDE clinical trial permit in January 2025, becoming the world's first bispecific antibody drug for fundus diseases to advance clinical trials simultaneously in both China and the United States.

OCUL101 is also the world's first bispecific antibody innovative therapy that simultaneously targets nAMD (neovascular age-related macular degeneration), DME (diabetic macular edema), and GA (geographic atrophy). Its unique dual-target mechanism achieves triple synergistic effects of "anti-angiogenesis, anti-inflammation, and neuroprotection," opening up a new treatment pathway for patients with fundus diseases.

In early 2025, the company successfully completed byLed by LongRiver Jiangyuan InvestmentOver 100 Million RMB in Series A Financing.